Key Points
- Axon Enterprise insider Isaiah Fields sold 2,000 shares on May 22 at an average price of $400 each, for a total of $800,000. After the sale, he still held 52,813 shares valued at about $21.1 million.
- The company recently reported stronger-than-expected quarterly results, posting earnings of $1.61 per share versus the $1.60 consensus and revenue of $807.35 million, up 33.7% year over year.
- Wall Street remains generally positive on Axon, with a consensus “Moderate Buy” rating and an average target price of $712.75, though some firms have recently trimmed their price targets.
Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) insider Isaiah Fields sold 2,000 shares of the business's stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $400.00, for a total value of $800,000.00. Following the transaction, the insider directly owned 52,813 shares in the company, valued at approximately $21,125,200. This represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Isaiah Fields also recently made the following trade(s):
- On Friday, February 27th, Isaiah Fields sold 2,000 shares of Axon Enterprise stock. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00.
Axon Enterprise Stock Performance
NASDAQ AXON opened at $385.30 on Wednesday. The company has a market cap of $31.06 billion, a P/E ratio of 154.74, a P/E/G ratio of 7.02 and a beta of 1.44. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The business's 50 day moving average price is $412.03 and its 200-day moving average price is $497.50. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $885.91.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.01. The firm had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company's revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.47 EPS. Sell-side analysts predict that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on AXON shares. UBS Group cut their target price on Axon Enterprise from $570.00 to $440.00 and set a "neutral" rating on the stock in a research report on Thursday, May 7th. William Blair restated an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. Wall Street Zen upgraded Axon Enterprise from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Zacks Research upgraded Axon Enterprise from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 19th. Finally, TD Cowen dropped their price objective on Axon Enterprise from $950.00 to $825.00 and set a "buy" rating for the company in a report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus target price of $712.75.
Check Out Our Latest Analysis on Axon Enterprise
Hedge Funds Weigh In On Axon Enterprise
A number of large investors have recently bought and sold shares of the business. Evergreen Capital Management LLC raised its position in Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock valued at $342,000 after purchasing an additional 15 shares in the last quarter. Monte Financial Group LLC raised its position in Axon Enterprise by 5.5% during the 3rd quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company's stock valued at $233,000 after purchasing an additional 17 shares in the last quarter. Wealth Alliance LLC raised its position in Axon Enterprise by 3.2% during the 3rd quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company's stock valued at $419,000 after purchasing an additional 18 shares in the last quarter. Commerzbank Aktiengesellschaft FI raised its position in Axon Enterprise by 4.5% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 439 shares of the biotechnology company's stock valued at $316,000 after purchasing an additional 19 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its position in Axon Enterprise by 0.5% during the 3rd quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company's stock valued at $2,848,000 after purchasing an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.
Axon Enterprise Company Profile
(
Get Free Report)
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
